[go: up one dir, main page]

MX2011012369A - Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa. - Google Patents

Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.

Info

Publication number
MX2011012369A
MX2011012369A MX2011012369A MX2011012369A MX2011012369A MX 2011012369 A MX2011012369 A MX 2011012369A MX 2011012369 A MX2011012369 A MX 2011012369A MX 2011012369 A MX2011012369 A MX 2011012369A MX 2011012369 A MX2011012369 A MX 2011012369A
Authority
MX
Mexico
Prior art keywords
pyrazolopyrimidines
kinase inhibitors
compounds
related heterocycles
kinases
Prior art date
Application number
MX2011012369A
Other languages
English (en)
Inventor
Mustapha Haddach
Joe A Tran
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of MX2011012369A publication Critical patent/MX2011012369A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos de la fórmula general (1) que inhiben cinasas seleccionadas (Pim y/o CK2 cinasas) y composiciones que contienen dichos compuestos. Estos compuestos y composiciones son útiles para tratar trastornos proliferativos tales como cáncer, así como otras condiciones asociadas con cinasa que incluyen inflamación, dolor, y ciertas infecciones y trastornos inmunológicos.
MX2011012369A 2009-05-20 2010-05-20 Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa. MX2011012369A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18009009P 2009-05-20 2009-05-20
US21831809P 2009-06-18 2009-06-18
PCT/US2010/035657 WO2010135581A1 (en) 2009-05-20 2010-05-20 Pyrazolopyrimidines and related heterocycles as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2011012369A true MX2011012369A (es) 2012-03-16

Family

ID=43126513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012369A MX2011012369A (es) 2009-05-20 2010-05-20 Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.

Country Status (15)

Country Link
US (1) US8367681B2 (es)
EP (1) EP2432473A4 (es)
JP (1) JP2012527479A (es)
KR (1) KR20120044305A (es)
CN (1) CN102458412A (es)
AU (1) AU2010249493A1 (es)
BR (1) BRPI1011066A2 (es)
CA (1) CA2762313A1 (es)
IL (1) IL216411A0 (es)
MX (1) MX2011012369A (es)
NZ (1) NZ596571A (es)
RU (1) RU2011151835A (es)
SG (1) SG176584A1 (es)
WO (1) WO2010135581A1 (es)
ZA (1) ZA201108622B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782684C (en) * 2009-12-04 2018-09-04 Mustapha Haddach Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
GB201107197D0 (en) * 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
WO2012170827A2 (en) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
TW201319063A (zh) * 2011-10-04 2013-05-16 Yakult Honsha Kk 以四氫噻唑衍生物或其鹽為有效成分之醫藥品
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
TW201932456A (zh) 2013-01-15 2019-08-16 美商英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
JP6023630B2 (ja) * 2013-04-03 2016-11-09 株式会社ヤクルト本社 チアゾロン誘導体
JP6378918B2 (ja) * 2013-04-03 2018-08-22 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とするPim阻害剤
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
AU2016219102B2 (en) * 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
MX2020010556A (es) 2018-04-13 2021-03-02 Sumitomo Pharma Oncology Inc Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN111499513B (zh) * 2020-04-24 2023-03-14 上海毕得医药科技股份有限公司 一种2,3,4,5-四溴苯甲酸酯的合成方法
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂
US12269826B1 (en) * 2023-11-16 2025-04-08 King Faisal University 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors
US12258345B1 (en) * 2023-12-12 2025-03-25 King Faisal University Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028535A1 (en) * 2002-09-26 2004-04-08 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JP5102212B2 (ja) * 2005-10-06 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
JP2009544723A (ja) * 2006-07-24 2009-12-17 スミスクライン・ビーチャム・コーポレイション Pi3キナーゼ阻害剤としてのチオゾリジンジオン誘導体
CA2667487C (en) * 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors

Also Published As

Publication number Publication date
US8367681B2 (en) 2013-02-05
WO2010135581A1 (en) 2010-11-25
EP2432473A1 (en) 2012-03-28
SG176584A1 (en) 2012-01-30
BRPI1011066A2 (pt) 2017-03-21
ZA201108622B (en) 2012-07-25
NZ596571A (en) 2013-03-28
US20100331314A1 (en) 2010-12-30
CA2762313A1 (en) 2010-11-25
IL216411A0 (en) 2012-02-29
CN102458412A (zh) 2012-05-16
EP2432473A4 (en) 2013-12-11
JP2012527479A (ja) 2012-11-08
KR20120044305A (ko) 2012-05-07
RU2011151835A (ru) 2013-06-27
AU2010249493A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
IN2012DN03112A (es)
IN2012DN03217A (es)
IN2012DN03213A (es)
WO2012170827A3 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
MX2011012037A (es) Compuestos de heteroarilo como inhibidores de pikk.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
NZ711376A (en) Heteroaryl compounds and uses thereof
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
NZ630925A (en) Pyrazolopyrimidine compounds as kinase inhibitors
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MY173126A (en) Arylquinazolines
GEP20125368B (en) Kinase inhibitors
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal